Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28577615 | 0.82 | GAA (0.59) | GAACA1CA2CA12CA9 | |
| SCHEMBL118977 | 0.78 | GAA (0.54) | GAACA1CA2CA12CA9 | |
| SCHEMBL360697 | 0.78 | GAA (0.54) | GAACA1CA2CA12CA9 | |
| SCHEMBL1721592 | 0.78 | GAA (0.54) | GAACA1CA2CA12CA9 | |
| SCHEMBL13783355 | 0.76 | GAA (0.52) | GAACA1CA2CA12CA9 | |
| SCHEMBL27524270 | 0.75 | CA1 (0.52) | GAACA1CA2CA12CA9 | |
| SCHEMBL6547519 | 0.75 | GAA (0.50) | GAACA1CA2CA12CA9 | |
| SCHEMBL2493552 | 0.75 | GAA (0.50) | GAACA1CA2CA12CA9 | |
| SCHEMBL7124034 | 0.74 | HTR6 (0.52) | GAACA1CA2CA12CA9 | |
| SCHEMBL28433392 | 0.73 | CA2 (0.60) | GAACA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5700799-A | MICROBIOCIDES FOR TREATING HUMAN OR ANIMAL DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-23 | — | — | US | claimed |
| CN-116964074-A | Peptides that modulate VEGF | IDP研发制药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-109071622-B | Peptides with anticancer activity | IDP研发制药有限公司（ES） | 2023-01-13 | — | — | CN | disclosed |
| CN-115135765-A | Chemically modified oligonucleotides targeting bromodomain-containing protein 4(BRD4) for immunotherapy | 菲奥医药公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114585370-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114502177-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114146056-A | Modular compositions for scavenging soluble biomolecules and methods related thereto | 纳米提克斯有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-113748116-A | Techniques useful for oligonucleotide preparation | 波涛生命科学有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-113383078-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-112812143-A | Triterpene saponin analogues | 佐剂技术公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-110582282-A | Triterpene saponin analogues | 佐剂技术公司 | 2019-12-17 | — | — | CN | disclosed |
| US-20040266825-A1 | N-formyl derivatives of paroxetine | HOORN HANS J | 2004-12-30 | — | — | US | disclosed |
| EP-1440067-B1 | N-FORMYL DERIVATIVES OF PAROXETINE | SYNTHON BV (NL) | 2004-12-22 | — | — | EP | disclosed |
| US-20040147497-A1 | N-formyl derivatives of paroxetine | HOORN HANS J (NL) | 2004-07-29 | — | — | US | disclosed |
| US-6703408-B2 | TREATING AN N-FORMYL PAROXETINE COMPOUND WITH A DE-FORMYLATION AGENT SELECTED FROM HYDROCHLORIC ACID, ACETIC ACID, FORMIC ACID, METHANE SULFONIC ACID, MALEIC ACID, AND TARTARIC ACID FORMS A SALT OF PAROXETINE | SYNTHON BCT TECHNOLOGIES, LLC | 2004-03-09 | — | — | US | disclosed |
| US-20030125560-A1 | N-formyl derivatives of paroxetine | SYNTHON IP INC. | 2003-07-03 | — | — | US | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-3988362-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125560-A1 | N-formyl derivatives of paroxetine | TPH1, MAOB, HTR1F | GAA 3683/4885CA1 4649/4885CA2 4785/4885 |
| US-20040147497-A1 | N-formyl derivatives of paroxetine | TPH1, MAOB, HTR1F | GAA 3683/4885CA1 4649/4885CA2 4785/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | GAA 3055/4885CA1 2629/4885CA2 1149/4885 |
| US-20040266825-A1 | N-formyl derivatives of paroxetine | TPH1, MAOB, HTR1F | GAA 3683/4885CA1 4649/4885CA2 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.